Biota reaps $4.2m from R&D Tax Incentive
Wednesday, 07 November, 2012
Biota (ASX:BTA) has revealed it has received a $4.2 million cash rebate under the government's R&D Tax Incentive.
The company said it will recognise the $4.2 million as a tax credit in its December quarterly financial filings.
Biota revealed in its FY12 annual report that it had submitted the tax credit claim, but did not recognise it in the financial statements for the year, stating that “directors believe it is appropriate to [first] understand how the offset will be administered by the ATO and AusIndustry.”
Shareholders in Biota last month approved a proposal for a reverse takeover of US-based, Nasdaq-listed Nabi Pharmaceuticals.
The merged company will have revenue generating products including flu drugs laninamivir (Inavir) and zanamivir (Relenza), and a development pipeline including treatments for human rhinovirus (HRV), respiratory syncytial virus (RSV) and Hepatitis C (HCV).
The company now expects to delist from the ASX and quote on the Nasdaq by November 9. Its shares were suspended from trading on the ASX on October 30, at a price of 57c.
Childhood epilepsy may lead to memory disorders later in life
Individuals who had childhood epilepsy have an increased accumulation of brain amyloid later in...
Milestone as mouse with two fathers reaches adulthood
Stem cell scientists have successfully used embryonic stem cell engineering to create a...
Scientists complete final chromosome in synthetic yeast genome
The synthetic chromosome includes features that enable researchers to generate genetic diversity...
